4. Late Effects after Allogeneic Hematopoietic Stem Cell Transplantation

  1. Bipin N Savani MD
  1. Shahrukh Hashmi1 and
  2. Mark R Litzow2

Published Online: 6 SEP 2013

DOI: 10.1002/9781118473306.ch4

Blood and Marrow Transplantation Long-Term Management: Prevention and Complications

Blood and Marrow Transplantation Long-Term Management: Prevention and Complications

How to Cite

Hashmi, S. and Litzow, M. R. (2013) Late Effects after Allogeneic Hematopoietic Stem Cell Transplantation, in Blood and Marrow Transplantation Long-Term Management: Prevention and Complications (ed B. N. Savani), John Wiley & Sons, Ltd, Oxford, UK. doi: 10.1002/9781118473306.ch4

Editor Information

  1. Professor of Medicine,Director, Long Term Transplant Clinic, Hematology and Stem Cell Transplantation Section, Vanderbilt University Medical Center, Nashville, TN, USA

Author Information

  1. 1

    Division of Blood and Marrow Transplantation, William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN, USA

  2. 2

    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN, USA

Publication History

  1. Published Online: 6 SEP 2013
  2. Published Print: 1 OCT 2013

ISBN Information

Print ISBN: 9781118473405

Online ISBN: 9781118473306

SEARCH

Keywords:

  • stem;
  • cell;
  • transplant;
  • allogeneic;
  • graft-versus-host disease;
  • late;
  • effects;
  • quality;
  • secondary

Summary

Worldwide, greater than 60 000 people undergo hematopoietic stem cell transplantation (HSCT) annually. Since the inception of HSCT in the treatment paradigm of human diseases approximately 50 years ago, substantial advances in HSCT techniques and supportive care have led to improvements in survival, but late effects of HSCT cause substantial morbidity and mortality. In the case of allogeneic HSCTs, immunosuppressive therapies and graft-versus-host disease are major contributors to these complications. The majority of the complications occur within a few years of allogeneic-HSCT; however the incidence of a few conditions (e.g., cardiovascular complications and secondary cancers) is highest at 6–10 years post-HSCT. Thus, these complications can be broadly divided into late effects (occurring after 6 months of HSCT) and very late effects (occurring after 5 years of HSCT). Management of specific late effects is discussed separately. The goals of this chapter include a comprehension of the basic concepts and identification of these effects.